Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery

BACKGROUND: Perioperative antiplatelet agents potentially increase bleeding after non–ST‐segment elevation (NSTE) acute coronary syndromes (ACS). The protease‐activated receptor 1 antagonist vorapaxar reduced cardiovascular events and was associated with increased bleeding versus placebo in NSTE ACS...

Descripción completa

Detalles Bibliográficos
Autores principales: van Diepen, Sean, Tricoci, Pierluigi, Podder, Mohua, Westerhout, Cynthia M., Aylward, Philip E., Held, Claes, Van de Werf, Frans, Strony, John, Wallentin, Lars, Moliterno, David J., White, Harvey D., Mahaffey, Kenneth W., Harrington, Robert A., Armstrong, Paul W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845287/
https://www.ncbi.nlm.nih.gov/pubmed/26672080
http://dx.doi.org/10.1161/JAHA.115.002546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845287/
https://www.ncbi.nlm.nih.gov/pubmed/26672080
http://dx.doi.org/10.1161/JAHA.115.002546

Ejemplares similares